Filter Results:
(353)
Show Results For
- All HBS Web
(353)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (71)
Show Results For
- All HBS Web
(353)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (71)
- August 2007
- Article
Financial Contracting in Biotech Strategic Alliances
Robinson, David, and Toby E. Stuart. "Financial Contracting in Biotech Strategic Alliances." Journal of Law & Economics 50, no. 3 (August 2007): 559–596.
Science Business: The Promise, the Reality, and the Future of Biotech
Why has the biotechnology industry failed to perform up to expectations despite all its promise? In Science Business, Professor Gary Pisano answers this question by providing an incisive critique of the industry. Pisano not only... View Details
- Fast Answer
Biotech and Pharmaceuticals: R&D spending, production cost
Where to find biotech and pharmaceuticals R&D spending and product cost data? Bloomberg – use BI function to locate R&D spending data Cortellis - special database on pharmaceuticals industry including R&D... View Details
- 26 Feb 2020
- News
Alumni-Led Biotech Developing Vaccine to Combat Coronavirus
prominent local scientists and biotech leaders—Bancel included—met this week at Harvard Medical School to brainstorm new approaches. That meeting is part of a recently announced $115 million collaboration between scientists at Harvard... View Details
- 15 Sep 2020
- Blog Post
One Month into the New MS/MBA Biotech
Harvard’s new MS/MBA Biotechnology: Life Sciences joint degree program confers an MBA from Harvard Business School and a Master of Science from the Graduate School of Arts and Sciences and Harvard Medical School in the Harvard Department of Stem Cell and Regenerative... View Details
- 01 Oct 2021
- News
New Biotech Joint Degree Program Kicks Off
director of joint degree programs at HBS. It takes full advantage of greater Boston’s position as one of the world’s largest biotech clusters. The joint degree integrates the essential lessons learned at the lab bench and in the corner... View Details
- March 2007
- Teaching Note
Monsanto: Realizing Biotech Value in Brazil (TN)
By: David E. Bell and Mary L. Shelman
- 23 Mar 2016
- News
Building a Biotech Business from Farmed Fish
Charlton Ames (MBA 1970) is chairman and vice president of business development for Sea Run Holdings, a virtual firm in Maine that develops innovative biologics and therapeutics from the blood of farmed salmon. In this video he explains the structure and goals of his... View Details
- October 2019
- Case
Kymera Therapeutics: Building a Biotech Execution Plan
By: Peter Barrett, Karim R. Lakhani and Kerry Herman
Barrett, Peter, Karim R. Lakhani, and Kerry Herman. "Kymera Therapeutics: Building a Biotech Execution Plan." Harvard Business School Case 620-017, October 2019.
- 03 Jul 2024
- Podcast
A Biotech Solution to Palm Oil Deforestation
Today’s episode is the fifth in our series on decarbonizing the roots of value chains, where we’re looking deep into supply chains that serve many industries. Previously we talked about green concrete, green steel, regenerative agriculture, and lab-grown cotton. Today... View Details
- 02 Mar 2016
- News
Drug ad backlash doesn’t deter Cambridge biotech
- 2006
- Book
Science Business: The Promise, the Reality, and the Future of Biotech
By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
Pisano, Gary P. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business School Press, 2006.
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Pharmaceutical Industry; San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- Fast Answer
Biotech and medical devices: Company Data and Analysis
Where can I find biotech and medical devices company financials and analysis? We suggest that you may use at least more than one of them for your company research. Capital IQ - Data on public and private companies, investment firms,... View Details
- 12 Jul 2015
- News
How Genzyme became a source of biotech executives
- 23 Sep 2013
- News
The Best Biotech Graduate Schools in Real Life
- 11 Jun 2009
- News
Despite Odds, Cities Race to Bet on Biotech
- October 2012
- Teaching Plan
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)
By: Robert F. Higgins
This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details
Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Biotechnology Industry; United States; San Diego
- March 2007
- Teaching Note
Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)
Teaching note to 706454. View Details